Fig. 3From: Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilatorMean (95% CI) change from baseline in a) trough and b) peak FEV1 (per protocol population). CI = confidence interval; FEV1 = forced expiratory volume in 1 sBack to article page